Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear

Drug Delivery and Translational Research

Volumn 5, Issue 4, 2015, Pages 332-345

  Rini, Christopher James ^a   McVey, Elaine ^a   Sutter, Diane ^a   Keith, Stephen ^a   Kurth, Heinz Joerg ^b   Nosek, Leszek ^b   Kapitza, Christoph ^b   Rebrin, Kerstin ^c   Hirsch, Laurence ^c   Pettis, Ronald J ^a  

^a BD Technologies   (United States)

^b Profil   (Germany)

^c BD Technologies   (United States)

Author keywords

Clinical research; Glucose; Glycemia; Insulin; Microneedle

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CARBOHYDRATE ANALYSIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; LIMIT OF DETECTION; MALE; MICRONEEDLE; NAUSEA; OPEN STUDY; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME; VOMITING; ANALYSIS; BLOOD; DEVICES; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; INTRADERMAL DRUG ADMINISTRATION; MICROINJECTION; NEEDLE; POSTPRANDIAL STATE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INJECTIONS, INTRADERMAL; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MICROINJECTIONS; NEEDLES; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 84938776912     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-015-0239-x     Document Type: Article

References (46)

1. American Diabetes Association. Postprandial blood glucose (consensus statement). Diabetes Care. 2001;24:775–8.
2. Freckmann G, Hagenlocher S, Baumstark A, et al. Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals. J Diabetes Sci Technol (Online). 2007;1(5):695–703.
3. Cherrington AD. The role of hepatic insulin receptors in the regulation of glucose production. J Clin Invest. 2005;115:1136–9.
4. Bolli GB, Di Marchi RD, Park GD, Pramming S, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia. 1999;42(10):1151–67.
5. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14(9):780–8.
6. Krasner A, Pohl R, Simms P, Pichotta P, Hauser R, De Souza E. A review of a family of ultra-rapid-acting insulins: formulation development. J Diabetes Sci Technol. 2012;6(4):786–96.
7. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012;6(4):728–42.
8. Cengiz E, Weinzimer SA, Sherr JL, et al. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatr Diabetes. 2013;14(3):168–73.
9. Fonte P, Araújo F, Reis S, Sarmento B. Oral insulin delivery: how far are we? J Diabetes Sci Technol. 2013;7(2):520–31.
10. Rao R, Mahant S, Chhabra L, Nanda S. Transdermal innovations in diabetes management. Curr Diabetes Rev. 2014;10(6):343–59.
11. Cavaiola TS, Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther. 2014;36(8):1275–89.
12. Henkin RI. Inhaled insulin—intrapulmonary, intranasal, and other routes of administration: mechanisms of action. Nutrition. 2010;26(1):33–9.
13. Pettis RJ, Harvey AJ. Microneedle delivery: clinical studies and emerging medical applications. Ther Deliv. 2012;3(3):357–71.
14. Hultström M, Roxhed N, Nordquist L. Intradermal insulin delivery a promising future for diabetes management. J Diabetes Sci Technol. 2014;8(3):453–7.
15. Kim Y-C, Park J-H, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547–68.
16. Donnelly RF, Raj Singh TR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv. 2010;17(4):187–207.
17. Harvey AJ, Kaestner SA, Sutter DE, Harvey NG, Mikszta JA, Pettis RJ. Microneedle-based intradermal delivery enables rapid lymphatic uptake and distribution of protein drugs. Pharm Res. 2011;28(1):107–16.
18. Pettis RJ et al. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. Diabetes Technol Ther. 2011;13(4):443–50.
19. McVey E et al. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion. J Diabetes Sci Technol. 2012;6(4):743–54.
20. Meric-Bernstam F et al. Toward nodal staging of axillary lymph node basins through intradermal administration of fluorescent imaging agents. Biomed Optics Express. 2014;5(1):183–96.
21. Milewski M et al. Analysis of the absorption kinetics of macromolecules following intradermal and subcutaneous administration. Eur J Pharm Biopharm. 2015;89:134–44.
22. McVey EA, Keith SC, Sutter DE, Judge K, Herr J, Pettis RJ. Proof of reliability of intradermal devices under extended wear basal/bolus infusion conditions. Poster abstract EASD Barcelona 2013; data submitted for publication.
23. Heinemann L, et al. Intra-dermal insulin lispro application with a new microneedle delivery system led to a substantially more rapid insulin absorption than subcutaneous injection. Diabetologia. Vol. 49. 233 Spring Street, New York, Ny 10013 USA: SPRINGER; 2006.
24. Gupta J, Felner EI, Prausnitz MR. Minimally invasive insulin delivery in subjects with type 1 diabetes using hollow microneedles. Diabetes Technol Ther. 2009;11(6):329–37.
25. Gupta J, Felner EI, Prausnitz MR. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol Ther. 2011;13(4):451–6.
26. Pettis RJ et al. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection. Diabetes Technol Ther. 2011;13(4):435–42.
27. Norman JJ et al. Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2013;14(6):459–65.
28. Mohammed YH, Yamada M, Lin LL, Grice JE, Roberts MS, Raphael AP, et al. Microneedle enhanced delivery of cosmeceutically relevant peptides inhuman skin. PLoS ONE. 2014;9(7), e101956.
29. Heinemann L, Krinelke L. Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol. 2012;6(4):954–64.
30. Gill HS, Denson D, Burris B, Prausnitz MR. Effect of microneedle design on pain in human subjects. Clin J Pain. 2008;24(7):585–94.
31. Laurent PE, Bonnet S, Alchas P, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine. 2007;25:8833–42.
32. Laurent A, Mistretta F, Bottigioli D, Dahel K, Goujon C, et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine. 2007;25:6423–30.
33. Gibney MA, Arce CH, Byron KJ, et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin. 2010;26:1519–30.
34. Luijf YM, Arnolds S, Avogaro A, et al. Patch pump versus conventional pump: postprandial glycemic excursions and the influence of wear time. Diabetes Technol Ther. 2013;15:575–9.
35. T1D exchange evaluates correlation between infusion set duration and FBG. (2014, July 7). Retrieved May 8, 2015, from https://t1dexchange.org/pages/t1d-exchange-evaluates-correlation-between-infusion-set-duration-and-fbg/.
36. Clausen TS, Kaastrup P, Stallknecht B. Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans. Diabetes Technol Ther. 2009;11(9):575–80.
37. Liu D et al. Insulin absorption is faster when keeping the infusion site in use for three days during continuous subcutaneous insulin infusion. Diabetes Res Clin Pract. 1991;12(1):19–24.
38. Swan KL et al. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care. 2009;32(2):240–4.
39. Olsson PO, Arnqvist H, Asplund J. No pharmacokinetic effect of retaining the infusion site up to four days during continuous subcutaneous insulin infusion therapy. Diabet Med. 1993;10(5):477–80.
40. Thethi TK et al. Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion. J Diabetes Complicat. 2010;24(2):73–8.
41. Schmid V et al. Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy—trouble starts on day 3. J Diabetes Sci Technol. 2010;4(4):976–82.
42. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. Diabetes. 2011;60(11):2672–82.
43. Elleri D, Dunger DB, Hovorka R. Closed-loop insulin delivery for treatment of type 1 diabetes. BMC Med. 2011;9(1):120.
44. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4(5):673–82.
45. Kildegaard J, Christensen TF, Hejlesen OK. Sources of glycemic variability—what type of technology is needed? J Diabetes Sci Technol. 2009;3(4):986–91.
46. Gupta J, Park SS, Bondy B, Felner EI, Prausnitz MR. Infusion pressure and pain during microneedle injection into skin of human subjects. Biomaterials. 2011;32(28):6823–31.